Background：Obiltoxaximab ETI-204, trade name Anthim is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody mAb developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority BARDA for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment in combination with appropriate antibacterial drugs and prophylaxis of inhalational anthrax.
